ABSTRACT
Diabetic neuropathy (DN) remains a debilitating complication of diabetes, characterized by chronic pain and progressive nerve damage. While current therapies often fall short, curcumin has emerged as a potent therapeutic candidate due to its pleiotropic pharmacological profile. This review evaluates the neuroprotective potential of curcumin, focusing on its ability to mitigate oxidative stress and systemic inflammation by modulating key signaling hubs, including Nrf2, MAPK, and NF‐κB. Preclinical evidence suggests that curcumin not only stabilizes glucose metabolism but also modulates the molecular pathways responsible for nerve degradation. However, its therapeutic translation is frequently limited by poor aqueous solubility and low bioavailability. We therefore highlight recent breakthroughs in nano‐drug delivery systems and novel formulations designed to enhance its metabolic stability. By synthesizing the latest mechanistic insights and delivery innovations, this review positions curcumin as a vital component in future integrative strategies for treating diabetic neuropathy.
Keywords: curcumin, diabetes, neuropathy, signalling, transcription factors
This review highlights curcumin's neuroprotective potential, showing how it mitigates oxidative stress and inflammation by modulating Nrf2, MAPK, and NF‐κB signaling. Preclinical data shows it stabilizes glucose metabolism and reduces nerve degradation. To address its low aqueous solubility and bioavailability, we showcase recent nano‐drug delivery systems that optimize therapeutic delivery.

Abbreviations
- FOM
Fundación Oftalmológica del Mediterráneo
- ERG
electroretinogram
- GPx
glutathione peroxidase
- SOD
superoxide dismutase
1. Introduction
1.1. Diabetic Neuropathy and its Global Prevalence
Diabetes mellitus (DM) is a collection of metabolic disorders characterized by elevated blood glucose levels (hyperglycemia), the presence of sugar in urine (glycosuria), increased lipid levels in the bloodstream (hyperlipidaemia), and protein depletion (negative nitrogen balance). These disorders stem from deficiencies in insulin synthesis, its efficacy, or a combination of both, resulting in elevated blood glucose levels before to and following meals [1].
Diabetes mellitus (DM) is a prevalent metabolic disorder characterized by elevated blood glucose levels (hyperglycemia). The increasing incidence and severe complications provide considerable threats to human health and life. Presently, around 537 million persons aged 20 to 79 (10.5% of this demographic) are afflicted with diabetes. The figure is projected to increase to 643 million by 2030 and 783 million by 2045. The management of diabetes and its complications incurs a minimum expense of 966 billion dollars, imposing a significant financial strain on both individuals and society [2].
Alongside the chronic difficulties of DM, patients have macroangiopathy microangiopathy and neuropathy all of which detrimentally impact their quality of life.
A recent analysis indicates that diabetic neuropathy impacts approximately 30% of hospitalized diabetic patients and 20%–30% of those in the community. Approximately 66% of individuals with type 1 diabetes and 59% of those with type 2 diabetes are predisposed to developing neuropathy [3, 4].
Approximately from 20 to 30 million individuals are afflicted with symptomatic diabetic neuropathy, a figure anticipated to increase by 2030 [5].
Chronic hyperglycemia is the main cause of the complex neurodegenerative disease known as diabetic nephropathy (DN), which arises from the interaction of metabolic, vascular, and neurodegenerative processes. Prolonged elevated blood sugar levels set off a series of metabolic disorders that eventually lead to oxidative stress and inflammation, aggravating nerve damage by producing excessive amounts of reactive oxygen species (ROS) and encouraging neuronal death. By increasing oxidative stress and impeding neural repair, inflammatory reactions mediated by proinflammatory cytokines and pathways, such as nuclear factor kappa B (NF‐κB) and Toll‐like receptor 4 (TLR4), exacerbate the illness. Neuronal death is caused by disruptions in lipid metabolism, and nerve regeneration is hampered by insulin resistance and neurotrophic factor deficits. Chronic neuropathic pain is caused by the ensuing neuronal hyperexcitability and microglial activation. DN mostly affects sensory and autonomic axons; motor axons are less severely impacted. The disorder manifests as a “stocking and glove” pattern of sensory loss and is defined by the “dying back” of distal sensory axons in a length‐dependent manner. Chronic hyperglycemia also targets Schwann cells, which in extreme situations results in demyelination characteristics. Axonal support, including cytoskeletal characteristics and axon‐Schwann cell connections necessary for intra‐axonal mRNA translation, is impacted by damage to Schwann cells. Dorsal root ganglia (DRG) sensory neurons also show altered phenotypes, including decreased neurofilament synthesis, endoplasmic reticulum stress, and modifications in important plasticity molecules like growth‐associated protein 43 (GAP43) and heat shock proteins, which result in mitochondrial dysfunction and loss of peripheral nerve function. In DRG neurons exposed to chronic diabetes, recent research has shown changes in mRNA and microRNA expression, emphasizing the elevation of pathways related to inflammation, bioenergetics, and lipid metabolism. Research on focused treatments was made easier by these discoveries [6].
Curcumin (diferuloylmethane), a natural substance derived from Curcuma longa (turmeric) of the Zingiberaceae family, belongs to the curcuminoid class. Historically, it has been utilized as a spice in curries and as a medicinal remedy for ailments such as asthma, allergies, anorexia, colds, coughs, liver disorders, and sinusitis. Currently, curcumin is acknowledged for its efficacy in controlling inflammatory disorders. Curcumin reduces postsurgical allodynia, alleviates diabetic neuropathic pain, inhibits the progression of diabetic neuropathy, and diminishes pain related to depression.
Curcumin, or diferuloyl methane, is a symmetrical chemical. The IUPAC designation is (1E,6E).‐1,7‐bis(4‐hydroxy‐3‐methoxyphenyl)‐1,6‐heptadiene‐3,5‐dione, has the chemical formula C21H20O6 and a molecular weight of 368.38 g/mol. The structure comprises two aromatic rings with o‐methoxy phenolic groups connected by a seven‐carbon chain including an α,β‐unsaturated β‐diketone moiety [7].
The diketone group experiences keto‐enol tautomerism, resulting in various conformers depending on the environment. Curcumin, in its crystalline form, occurs as a cis‐enol isomer, stabilized through hydrogen bonding. In non‐polar and moderately polar solvents, the enol form exhibits greater stability than the keto form by 5–8 kcal/mol, contingent upon the solvent used. The molecule displays extensive π‐conjugation, leading to a delocalized electron cloud. “The stereochemistry of curcumin is defined strictly by the geometry of its central aliphatic chain, specifically the E/Z (cis–trans) configuration across the C1 = C2 and C6 = C7 double bonds of the heptadienone linker. The naturally isolated compound exists predominantly in the thermodynamically stable (1E, 6E)$configuration. In contrast, the terminal 4‐hydroxy‐3‐methoxyphenyl rings are planar aromatic systems; hence, the relative positions of their hydroxy and methoxy groups do not constitute geometric isomerism.” The dipole moment in the ground state is 10.77 D [8, 9].
Curcumin (Figure 1) exhibits hydrophobic properties, possessing a logP value of approximately 3.0. It is almost insoluble in water but readily dissolves in polar solvents such DMSO, methanol, ethanol, acetonitrile, and chloroform. Its solubility in hydrocarbons such as cyclohexane and hexane is restricted. Curcumin's absorption spectra have two principal peaks: one inside the visible spectrum (410–430 nm) and another in the ultraviolet range (265 nm). The molar extinction coefficient of methanol at 425 nm is 55,000 dm3·mol− 1·cm− 1 [9].
FIGURE 1.

Structure of Curcumin [15].
Curcumin aids in reducing cholesterol and blood glucose levels in diabetes, while enhancing insulin sensitivity [10].
It activates the heme oxygenase 1 (HO‐1) gene, promotes glucose absorption, and elevates the expression of GLUT2, GLUT3, and GLUT4 genes. Curcumin further stimulates PPAR‐γ, Nrf2, AMPK, and free‐radical scavengers in diabetic animal models [11].
It can restore the control of insulin receptors and malate dehydrogenase, modulate protein kinase B (Akt) activity, and mitigate the hyperactivity of β2‐adrenoceptors in the skeletal muscles of streptozotocin‐induced diabetic rats.
Moreover, curcumin exhibits potent antioxidant capabilities, diminishing reactive oxygen species (ROS) and lipid peroxidation in numerous experimental investigations [12].
2. Sources of Curcumin
2.1. Natural Source
2.1.1. Plants
Turmeric (Curcuma longa) is the principal natural source of curcumin, with dry turmeric powder comprising 2%–8% curcuminoids, of which 70%–80% is curcumin. It is indigenous to South Asia, especially India, and is extensively farmed in tropical places worldwide. Turmeric is utilized in culinary applications as well as in traditional medicine and contemporary health supplements for its therapeutic properties. Other species within the Curcuma genus, including Curcuma aromatica and Curcuma zedoaria, also possess curcumin in lesser quantities and are utilized for medicinal and culinary applications in specific regions. Plants such as ginger (Zingiber officinale), which is part of the same family, contain trace levels of curcumin and other phenolic compounds, enhancing their therapeutic properties [13].
2.1.2. Fruits
Curcumin is not abundantly present in most fruits; nonetheless, curcumin extracted from turmeric is occasionally used into fruit‐based products to augment its antioxidant characteristics or function as a natural coloring agent.
2.1.3. Beverages
While curcumin is not inherently present in beverages, turmeric or its derivatives are frequently incorporated into many drinks. Traditional beverages such as turmeric milk, prepared by combining turmeric powder with milk and spices like cinnamon and ginger, are recognized for their immune‐enhancing and anti‐inflammatory attributes. Turmeric tea, made by boiling turmeric root or powder in water is a widely recognized herbal medicine that can be augmented with ingredients such as ginger, honey, or lemon. Contemporary functional beverages, such as turmeric shots, curcumin‐infused smoothies, and turmeric lattes, integrate curcumin for its health advantages. Moreover, curcumin is sometimes used into alcoholic beverages, such turmeric‐infused beers and cocktails, to attract health‐conscious consumers [13].
2.1.4. Processed and Enriched Products
Owing to its restricted natural presence outside turmeric, curcumin is integrated into numerous processed items. This encompasses nutraceuticals, including capsules and tablets with standardized curcumin extracts, functional foods such as curcumin‐enhanced protein bars, cereals, and snacks, in addition to beverages like health drinks and energy drinks fortified with curcumin [14].
2.2. Overview of Methods Used to Extract and Isolate Curcumin from Natural Sources [15]
2.2.1. Pre‐Processing
Turmeric rhizomes undergo a preparation procedure to assure readiness for extraction. This process begins with washing to eliminate dirt and impurities, hence ensuring the cleanliness of the raw material. Subsequently, the rhizomes are meticulously desiccated to eliminate moisture, which is crucial for effective grinding and to avert deterioration. Upon drying, the rhizomes are pulverized into a fine turmeric powder, which acts as the precursor for curcumin extraction.
2.2.2. Extraction
Curcumin is derived from turmeric powder by either traditional or contemporary methods. Traditional techniques, such Soxhlet extraction and maceration, depend on solvents and are often time‐consuming and labor‐intensive. Conversely, contemporary techniques such as Ultrasound‐Assisted Extraction (UAE), Microwave‐Assisted Extraction (MAE), and Supercritical CO2 Extraction (SCE) provide expedited and more effective methodologies. These sophisticated techniques employ innovative strategies to optimize extraction efficiency while preserving curcumin quality.
2.2.3. Analysis
Upon extraction, the curcumin is subjected to rigorous testing for quality and purity. This is executed via an HPLC‐MS system (high‐performance liquid chromatography‐mass spectrometry), a sophisticated technology that identifies and quantifies chemical components. The testing verifies the molecular structure of curcumin and assures compliance with quality requirements, rendering it appropriate for use in medicines and nutraceuticals (Figure 2).
FIGURE 2.

Methods of extraction and isolation of curcumin.
3. Pharmacological Properties of Curcumin
3.1. Mechanism of Action of Antioxidant Effect
3.1.1. Inhibition of Lipid Peroxidation
One significant effect of oxidative stress is lipid peroxidation, which produces harmful aldehydes such 4‐hydroxynonenal (4‐HNE) and malondialdehyde (MDA), which cause tissue and cellular damage. As a potential indicator of oxidative damage, elevated MDA levels have been linked to oxidative stress in hepatitis C, HIV, retinal diseases, psoriasis, and other inflammatory skin ailments. Chronic hyperglycemia in diabetic neuropathy raises reactive oxygen species, which damage membranes and myelin, disrupt nerve transmission, and cause neuropathic symptoms by attacking neuronal membrane lipids and promoting lipid peroxidation. Through its strong antioxidant and free‐radical‐scavenging capabilities, curcumin inhibits this process by lowering lipid peroxidation and the production of harmful aldehydes as seen in rodent rat model. Additionally, it helps preserve the integrity of neuronal membranes and strengthens endogenous antioxidant defenses, which may prevent oxidative nerve damage and the advancement of diabetic neuropathy [16].
3.1.2. Induction of enzymes GPx and SOD
By activating enzymes like glutathione peroxidase (GPx) and superoxide dismutase (SOD), curcumin strengthens the body's natural antioxidant defenses and lowers oxidative stress and lipid peroxidation. Oxidative stress‐related diseases including HIV and hepatitis C have been linked to decreased GPx activity, and lipid peroxidation products like 4‐HNE may further reduce GPx function. Because of its antioxidant properties, curcumin may be able to reverse the effects of oxidative stress, which can lower glutathione levels and raise MDA in ophthalmic illnesses and cause retinal malfunction. Additionally, curcumin increased orthokeratosis in mouse skin and showed greater topical antioxidant and protective properties than ebselen in experimental experiments, indicating potential therapeutic efficacy in oxidative skin illnesses like psoriasis.
3.1.3. Reduction in Peroxynitrite Formation by Inhibiting iNOS and Directly Scavenging Activity of Peroxynitrite
Besides the previously discussed antioxidant methods, curcumin diminishes peroxynitrite production via decreasing iNOS (inducible nitric oxide synthase) and directly scavenges peroxynitrite. The antioxidant capabilities are likely a crucial element in its neuroprotective benefits. Curcumin can safeguard neurones from damage induced by cerebral ischaemia by neutralizing free radicals such as peroxynitrite and enhancing cerebral blood flow via the generation of nitric oxide (NO). This polyphenolic antioxidant can traverse the blood‐brain barrier, providing protection against cerebral ischaemic damage. Curcumin therapy has demonstrated the ability to diminish peroxynitrite production, thereby reducing tyrosine nitration in cytosolic proteins [17].
3.1.4. Chelation of Metal Ions
The Fenton reaction entails the transformation of two molecules of hydrogen peroxide into hydroxyl radicals and water. During this process, ferrous iron (Fe+2) is oxidized by hydrogen peroxide to become ferric iron (Fe+3), resulting in the generation of a hydroxyl radical and a hydroxyl anion. The hydroxyl radical is among the most detrimental ROS for neurones. Iron (Fe+3) is subsequently reduced to Fe+2 by hydrogen peroxide, resulting in the release of a peroxide radical and a proton. Curcumin aids in safeguarding against this harm by chelating metal ions, including iron, lead, and cadmium (Figure 3). It has been demonstrated to safeguard rat hippocampus cells from lead‐induced injury and diminish lipid peroxidation instigated by lead and cadmium in rat brain tissue by chelating these metals and mitigating their neurotoxicity [18]
FIGURE 3.

Mechanism of action of curcumin as anti‐oxidant agents.
3.2. Mechanism of Action of Anti‐inflammatory Effect
In cancer, inflammation and tumor growth are significantly influenced by arachidonic acid metabolism via the cyclooxygenase (COX) pathway (Figure 4). COX‐2 is induced by inflammatory cytokines, growth factors, oncogenes, and signals that promote tumor growth, whereas COX‐1 is constitutively produced and sustains normal physiological functioning. The development and progression of a number of cancers, including colorectal, breast, lung, pancreatic, gastric, and prostate cancers, have been linked to overexpression of COX‐2, which increases prostaglandin synthesis. As a result, modifying the COX‐2 pathway is a crucial therapeutic approach for both preventing and treating cancer [19].
FIGURE 4.

Mechanism of action of curcumin as anti‐inflammatory agent. COX: Cyclooxygenase; HPETE: Hydroperoxyeicosatetraenoate; LOX: Lipoxygenase; LT: Leukotriene; PL; phospholipase; PG: Prostaglandin; TX: thromboxane.
3.2.1. Anti‐Inflammatory Pathways
Curcumin exhibits potent anti‐inflammatory properties by influencing critical variables associated with diabetes. It obstructs the NF‐κB signalling pathway, which is accountable for the synthesis of pro‐inflammatory cytokines such as TNF‐α, IL‐6, and IL‐1β. Curcumin diminishes cytokine production and inflammation by inhibiting NF‐κB activation. Curcumin additionally inhibits the c‐Jun N‐terminal kinase (JNK) and mitogen‐activated protein kinase (MAPK) pathways, which are implicated in inflammatory stress and β‐cell dysfunction. This safeguards the pancreatic β‐cells, which are crucial for diabetes management. Research indicates that curcumin can regulate levels of inflammatory markers, including TNF‐α and RANTES, thereby reinforcing its anti‐inflammatory function. Furthermore, curcumin enhances redox equilibrium and obstructs pathways activated by lipopolysaccharides and ROS, hence diminishing the chronic inflammation typically associated with diabetes [20].
3.2.2. Insulin Sensitivity
Although the majority of the mechanistic evidence comes from cellular and animal research, curcumin may increase insulin sensitivity through a variety of interrelated processes. According to experimental results, curcumin may improve IRS‐1 activity and glucose absorption by enhancing PI3K/Akt‐mediated insulin signaling and reducing excessive activation of stress‐related ERK/JNK pathways. Improved insulin responsiveness in experimental diabetic models has also been linked to IRS‐1 and Rac1 modulation. Moreover, Nrf2 pathway activation may lessen inflammation and oxidative damage, hence indirectly promoting insulin signaling. Curcumin may also affect JAK/STAT and STAT3‐related inflammatory pathways. However, rather than explicitly verifying these biological pathways, clinical investigations mainly show improvements in metabolic outcomes. Modest decreases in fasting blood glucose, HbA1c, fasting insulin, and HOMA‐IR are suggested by randomized studies and meta‐analyses. Curcumin has the potential to increase insulin sensitivity overall, but more well planned clinical research is required to pinpoint its exact processes [21, 22].
3.2.3. Oxidative Stress Reduction
Oxidative stress significantly contributes to the onset and advancement of diabetes, mostly by elevating ROS generation, which adversely affects pancreatic β‐cells. (Figure 5) Curcumin mitigates oxidative stress by stimulating the Nrf2‐Keap1 pathway, hence enhancing the synthesis of antioxidant enzymes such as SOD and glutathione peroxidase. This mitigates cellular damage from reactive oxygen species and inhibits β‐cell apoptosis. Curcumin directly neutralizes free radicals, hence reducing oxidative damage. Curcumin administration in diabetic animals has demonstrated the ability to restore redox equilibrium, diminish lipid peroxidation, and enhance mitochondrial function. Curcumin mitigates oxidative stress, so safeguarding β‐cells and enhancing insulin sensitivity, providing a twofold advantage in diabetes management [23].
FIGURE 5.

The Antioxidant and Cytoprotective Effects of Curcumin via Nrf2 Pathway Activation.
3.3. Mechanism of Immunomodulatory activities‐
Table 1 represents the study design and various immunomodulatory activities of curcumin.
TABLE 1.
In vitro and in vivo studies investigating the pharmacological properties of Curcumin.
| Main constituent | Subjects | Study design | Immunomodulatory activities | References |
|---|---|---|---|---|
| Curcumin | Healthy albino mice | In Vivo | White blood cell production and weight lymphoid organs | [24] |
| Dendric cells | In vitro | Surface molecule expression | [25] | |
| Dendric cells | In vitro | Cytokine production | [25] | |
| Dendric cells | In vitro | Phosphorylation of mitogens induced protein kinases and NF‐kB translocation | [25] | |
| Bronchoalveolar of Balb/c mice | In vivo | Allergic response | [16] | |
| Bronchoalveolar of Balb/c mice | In vivo | Cytokine production | [16] | |
| PBMCs | In vitro | T‐cell proliferation | [26] | |
| PBMCs | In vitro | Cytokine production | [26] | |
| PBMCs | In vitro | NF‐kB | [26] | |
| Erythroleukemic cell line K562 | In vitro | Cytotoxicity | [26] | |
| Lupus BALB/c mice | In vivo | Adaptive immune response | [27] | |
| Lupus BALB/c mice | In vivo | Antinuclear antibody levels | [27] | |
| Monocytes and liver macrophages | In vivo | ROS production | [28] | |
| Monocytes and CD4 cells | In vivo | TNF‐alpha &IFN‐gamma production | [28] | |
| Fish | In vivo | Immune response | [29] |
4. In Vitro Studies
4.1. Effects of Curcumin on Glucose Uptake in Cells
Curcumin enhances glucose absorption in insulin‐sensitive cells via multiple mechanisms:
GLUT Translocation: Curcumin promotes the translocation of glucose transporter proteins, such as GLUT1 and GLUT4, to the cell membrane, facilitating glucose uptake into cells.
Activation of PI3K/Akt: It stimulates the PI3K/Akt pathway, essential for insulin functionality and glucose transport [30].
ERK/JNK Inhibition: Curcumin enhances insulin receptor substrate (IRS) function and improves glucose absorption in insulin‐resistant cells by diminishing the phosphorylation of ERK and JNK [31].
Experimental Findings: Research on HepG2 cells indicates that curcumin and its metabolites augment glucose absorption via modulating these pathways, while curcumin furthermore normalizes GLUT1 expression in diabetes animals [31].
4.2. Impact on Insulin Sensitivity and Signaling
Curcumin has been extensively researched for enhancing insulin sensitivity. IRS‐1 and Rac1 Enhancement: It elevates the concentrations of IRS‐1 and Rac1, critical proteins in insulin signalling. The PI3K/AKT/GSK3β pathway: Curcumin works on this pathway, which is essential for insulin signalling and glucose metabolism. Curcumin diminishes the expression of SOCS3 and STAT3, both of which are implicated in insulin resistance. Reduction of Inflammation: Curcumin mitigates chronic inflammation linked to insulin resistance by blocking inflammatory pathways such as NF‐κB and decreasing pro‐inflammatory cytokines, including TNF‐α and IL‐6.
Experimental Evidence: In HepG2 cells, curcumin mitigated insulin resistance induced by elevated glucose levels and enhanced glucose absorption [22].
4.3. Antioxidant Properties and Role in Preventing Oxidative Stress
The potent antioxidant properties of curcumin are crucial in combating oxidative stress, a significant factor in the evolution of diabetes.
Curcumin promotes the Nrf2‐Keap1 pathway, enhancing the production of antioxidant enzymes such as SOD and catalase.
Curcumin directly neutralizes ROS, hence mitigating oxidative damage to pancreatic β‐cells.
Mitochondrial Protection: It aids in averting mitochondrial malfunction by re‐establishing redox equilibrium, hence facilitating optimal cellular energy consumption.
Experimental Findings: In vitro studies demonstrate that curcumin diminishes reactive oxygen species (ROS), enhances antioxidant enzyme activity, and safeguards β‐cells from apoptosis under hyperglycaemic circumstances [32].
5. Omics Methods to Study Curcumin in Diabetic Neuropathy (DN) [33, 34]
To elucidate multi‐modal effects of curcumin in DN one needs to use systems biology methods that would go beyond conventional molecular analyses in bulk tissue. Single cell transcriptomics, metabolomics, and proteomics would provide resolution of cell type‐specific responses, metabolic changes, signaling networks affected by curcumin and its novel derivatives in diabetic peripheral nervous system.
5.1. Single‐Cell Transcriptomics (scRNA‐seq): Insights into Cellular Diversity and Microenvironmental Dynamics
As DN involves interactions of several cell types in a very heterogeneous microenvironment of sensory neurons, Schwann cells, satellite glial cells, and immune cells, bulk transcriptomics fails to show the cell type‐specific effects. Conversely, single‐cell transcriptomics (scRNA‐seq) provides an insight into the effect of curcumin on the cellular heterogeneity and microenvironmental dynamics.
5.2. Glial Modulation and Neuroinflammation
scRNA‐seq shows that curcumin prevents pathological activation of the specialized types of glia through the normalization of the excess of EGFR expression, which is the major inducer of neuroinflammation and reactive gliosis. Consequently, curcumin prevents microglial and astrocytic polarization into pro‐inflammatory phenotype.
5.3. Inhibition of Inflammatory Cascades
Single‐cell sequencing identifies the effect of curcumin on the expression of crucial pro‐inflammatory downstream effectors in the form of JUN and TNF in specific single‐cell clusters. Such a reduction in the level of the above molecules leads to inhibition of macrophage infiltration into DRG and to pain signaling suppression.
5.4. Transcriptional Neuroprotection
The scRNA‐seq technique highlights the effect of curcumin on restoration of the expression of Brain‐Derived Neurotrophic Factor (BDNF) in nociceptors, enabling axon regeneration and synaptic dysfunction prevention.
5.5. Metabolomics: Normalization of Metabolic Regulation in Terms of DN
The metabolomics approach uncovers the changes in the biochemistry caused by curcumin (especially in case of optimized dose, e.g., 100 mg/kg), thus showing the ability of curcumin to restore metabolic regulation in terms of interconnected networks.
5.5.1. One‐Carbon and Trans‐Sulfuration Pathways
The perturbations in Cysteine and Methionine Metabolism are affected by the activity of such intermediates as 5'‐S‐methyl‐5'‐thioadenosine, L‐methionine, 2‐oxobutanoate, and O‐phospho‐L‐serine, which results in the normalization of one‐carbon metabolism and provision of the precursors for cellular methylation.
5.5.2. Glutathione Biosynthesis and Redox Defense
Being the donor of cysteine, which serves as the limiting substrate for glutathione synthesis, curcumin activates the Taurine and Hypotaurine Metabolism pathway providing antioxidant defense against ROS.
5.5.3. Neurotransmitters and Structural Proteins
The intersections of Arginine and Proline Metabolism pathway and glutathione biosynthesis pathway (via spermidine and L‐glutamic acid) indicate the possibility of restoration of metabolic balance essential for GABAergic/NMDA receptor signaling.
5.5.4. Proteomics and Signal Transduction
Characterization of MAPK Cascade and the Functional Proteome‐ Proteomics measures the protein networks, kinase chains and other protein changes that curcumin affects in nerve tissue samples. Proteomic profiling shows that curcumin works in two ways: it fights neuroinflammation. It helps nerve repair. Curcumin does not just target a pathway; it changes the whole MAPK signaling chain. When we combine scRNA‑seq, metabolomics and proteomics curcumin look more than an antioxidant. It becomes a treatment that works through parts of the body for diabetic neuropathy [35].
In conclusion scRNA‑seq allows us to determine which particular cellular types are involved (glia vs. Sensory neurons). Proteomics defines the functional kinase networks (EGFR/MAPK/BDNF) being acted on in these cellular types. Metabolomics measures physiological recovery through antioxidant, trans‐sulfuration and neurochemical pathways. Only by using this combined approach can we see how curcumin acts and which molecules it targets. Recent single‑cell studies, like have found the cell types—DRG neurons, satellite glial cells and Schwann cells—that play a role in nerve pain and diabetic peripheral neuropathy. Also, research on curcumin variants has reversed pain from light touch and improved nerve signals in diabetic neuropathy animals. Lowering molecules, like TNF‑α in the brain shows yet another proof that curcumin protects nerves [30].
6. Effects of Curcumin in Managing Diabetes: Preclinical Studies
Spranger et al. [36] found that elevated levels of the inflammatory cytokine IL‐6 were an independent predictor of occurrence type 2 diabetes in a European population. Curcumin supplementation may reduce circulating IL‐6 levels, according to a recent meta‐analysis. Two randomized, placebo‐controlled studies in individuals with type 2 diabetes found that curcumin reduces circulating IL‐6 and TNF‐α levels [36].
One of the most significant concerns about curcumin/curcuminoids' potential as medicinal agents has been their ability to reach their target. In a recent publication, the therapeutic capabilities of curcuminoids were questioned, owing to their low stability and pharmacokinetic features [37]. Indeed, curcumin is poorly absorbed and readily destroyed, resulting in limited bioavailability [38, 39]. That is why many ways to increasing curcumin bioavailability have been tested, including piperine co‐administration [40], curcumin nanomicelles [41], and phytosomes (a lecithin formulation) [42]. The lecithinized curcumin delivery method was evaluated in patients with diabetes mellitus suffering from microangiopathy and retinopathy at a dose similar to 200 mg/day while keeping the original medicine. The authors discovered good microcirculatory benefits [43].
Another worry is curcumin's effectiveness, which is based on the inconsistent nature of its glucose‐lowering effects in double‐blind placebo‐controlled trials, as well as the number of articles indicating that curcumin can benefit a wide range of conditions [48]. Curcumin may have therapeutic effects due to its inhibitory effect on GSK‐3β, which regulates the activity of many factors upstream and downstream and is involved in the pathophysiology of many diseases, such as diabetes mellitus, cancer, malaria, and Alzheimer disease [45]. However, Nelson et al. [46] suggest that the stability of curcumin should be carefully reviewed before considering GSK‐3β activity assays (and other assays too).
Again, while curcumin's hypoglycemic qualities have varied among trials, its hypolipidemic effects appear to be more consistent, with the exception of extremely low dosages. In addition to the fact that a curcumin dosage has not been defined, various formulations have been utilized in previous research, which may have influenced the reported results (Table 2).
TABLE 2.
Summary of clinical trials of curcumin in diabetes mellitus.
| Type of study | Characteristics of patient (n) | Curcumin or curcuminoids/dose/time of treatment | Hypoglycemic effect (% of decrease in fasting blood glucose) | Main findings | Reference |
|---|---|---|---|---|---|
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Type 2‐diabetes (n = 106 placebo group, n = 107 curcuminoid group) | Ethanolic curcuminoid extract/1500 mg of curcuminoids/day/6/months | Significant difference | Improvement of related atherogenic risk parameters (e.g., pulse wave velocity), increase serum adiponectin, decrease leptin, decrease HOMA index, improved lipid profile, decrease visceral and total fat. | [32] |
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Type 2 diabetes, 18‐65 years old (n = 118) | Capsule containing 5 mg of piperine + 500 mg of curcuminoid powder/12 weeks | No significant difference | Improvement of all the components of lipid profile, except for LDL‐C and triglycerides, decrease Lp)a). | [53] |
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Overweight/obese type 2 diabetic patients (n = 50 placebo, n = 50 curcuminoids) | Curcuminoids/300 mg/day/3 months | Significant difference (15%) | Decrease fasting blood glucose and glycosylated hemoglobin, decrease HOMA index, decrease total fatty acids, decrease triglycerides, decrease lipoprotein lipase activity | [54] |
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Type‐2 diabetic patients, with conventional antidiabetic therapy (n = 35 nanocurcumin group, n = 35 placebo group) | Curcumin nano‐micelle/80 mg/day/3 months | Significant difference (11%) | Decrease fasting blood glucose and glycosylated hemoglobin, improved lipid profile. | [20] |
| Non‐controlled before and after study | Patient with type 2 diabetes and diabetic kidney disease, some of them taking conventional medication | Commercial turmeric formulation/500 mg/day/15‐30 days | No significant difference |
Activation of the Nrf2 system Decrease urinary microalbumin excretion, increase antioxidant enzymes, decrease LDL‐cholesterol |
[21] |
| Pilot study (Placebo‐controlled study) |
Patient with Type 2 diabetic proteinuric chronic kidney disease (= 23 placebo, n = 28 curcumin) There was another group with nondiabetic proteinuric chronic kidney disease. |
Commercial turmeric formulation 980 mg curcumin/g)/320 mg of curcumin/day/8weeks | No significant difference | Enhancement of the antioxidant capacity of plasma, no improvement of lipid profile, no activation of Nfr2 nor effect on activity of antioxidant enzymes. | [22] |
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Patient with overt type 2 diabetic nephropathy, normal kidney function, taking ACE‐I and/or angiotensin receptor blockers (n = 20 placebo, n = 20 curcumin) | Encapsulated powdered turmeric rhizomes/1500 mg turmeric (66.3 mg of curcumin)/day/2 months | No significant difference | Decrease TGF‐β and IL‐8 in serum and protein excretion in urine. No significant changes in lipid profile. | [55] |
| Randomized, double‐blinded, and placebo‐controlled clinical trial | Individuals with prediabetes (n = 240) | Curcuminoid capsules/1500 mg of curcuminoids/day/9 months | Significant difference (17%) | Prevention of incident cases of type 2 diabetes, decrease glucose, decrease glycosylated hemoglobin, decrease HOMA index, decrease adiponectin, decrease C‐peptide. | [56] |
7. Effects of Curcumin in Managing Diabetes: Clinical Studies
A study found that curcuminoids (1000 mg/day) mixed with piperine had no effect on glucose and glycosylated hemoglobin levels after twelve weeks of treatment [47]. However, curcumin administration did reduce malondialdehyde levels and increase total antioxidant capacity and SOD1 activity. In another publication, the same research group [48] revealed that curcumin therapy improved patients' lipid profiles by increasing HDL cholesterol and decreasing Lp (a). Importantly, Lp (a) is a plasma lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B‐100, which has been linked to an increased cardiovascular risk. Given the scarcity of pharmacological alternatives to reduce its levels [49, 50], curcuminoids may represent a viable option to alleviate the complications associated with elevated levels of Lp (a) in diabetes mellitus.
Chuengsamarn et al. [32] conducted one of the biggest randomized, double‐blind, placebo‐controlled studies using curcumin, with a period of 9 months and a sample size of 240. However, this experiment was employed for preventative reasons in a pre‐diabetic population. Unlike previous research, interaction from other drugs often administered for diabetes mellitus was avoided. Interestingly, none of the subjects in the curcumin‐treated group (1500 mg of curcuminoids per day) developed diabetes mellitus after 9 months of treatment, whereas 16.4% of the placebo group did [51]. Weight and waist circumference were found to be improved, as were glucose, insulin, and C‐peptide concentrations; adiponectin levels were raised; and insulin resistance was decreased [51]. Later, this group of researchers performed another double‐blind placebo‐controlled study with an ethanolic extract of curcumin, at the same previous dose, in type‐2 diabetes mellitus patients [52]; the main finding of this study was a reduction in the atherogenic risk, as shown by a decreased pulse wave velocity (a surrogate marker of atherosclerosis), which was also accompanied by a series of changes in metabolic parameters, such as decreased leptin, triglyceride among others.
According to the clinical data, curcumin and curcuminoids' hypoglycemic effectiveness varies significantly depending on the patient's characteristics, research design, treatment duration, dose, formulation, and bioavailability. HbA1c, insulin resistance, and fasting glucose all improved more when higher doses (e.g., 1500 mg/day) were given for longer periods of time [32, 54]. However, although nano‐curcumin showed notable effects at only 80 mg/day, likely because of increased bioavailability, dose alone could not determine efficacy [20]. On the other hand, although metabolic indicators were improved, piperine‐enhanced curcumin did not significantly lower glucose [53]. Limited hypoglycemia effects were often observed in short‐duration studies and conventional turmeric formulations [21, 22, 55]. Inconsistent results are also caused by variations in baseline metabolic status, disease severity, concurrent medications, and research quality. Overall, curcumin exhibits encouraging metabolic and renoprotective properties; nevertheless, to prove conclusive clinical efficacy, standardized formulations and sufficiently powered long‐term trials are needed.
8. Clinical Implications and Future Directions
The evidence in relation to the hypoglycemic effect of curcumin is not very consistent; however, curcumin has the potential of improving the metabolic profile of patients with diabetes mellitus, mainly with regard to lipid levels, and reducing the associated complications. In addition, curcumin could have interesting interactions with conventional antidiabetic drugs that can positively affect diabetes treatment. Therefore, the use of curcumin as a coadjutant for diabetes mellitus therapy is a topic that merits to be considered. Also, the biological activity of other compounds in turmeric deserves to be well characterized, because those compounds could also be crucial for the therapeutic effects of Curcuma longa. Finally, considering those clinical trials on curcumin antidiabetic properties are no conclusive and many issues regarding its bioavailability need to be resolved, some questions emerge: despite its pharmacokinetic issues, is curcumin able to produce pharmacological effects at tiny concentrations? Is there a point of convergence for diabetes mellitus and other diseases in which curcumin has been reported to exert a beneficial effect? And if this is true, is that point of convergence a target for curcumin? A plausible candidate is GSK‐3b, as it is linked to diabetes, neurodegeneration, cancer and other pathologies; however, it is necessary to improve the lab biological assays related to this molecule to solidly affirm that it represents a good target for curcumin.
8.1. Bridging the Gap Between Preclinical results and inconsistent Clinical Results
One of the major challenges is the translation of the impressive efficacy of curcumin in vitro and in animal models to human clinical trials. Preclinical models demonstrate wide bioactivity, whereas primary metabolic and renal endpoints in clinical trials are inconsistent. 2. Critical Comparison of Conflicting Findings & Limitations Based on a critical analysis of study designs, contradicting clinical findings can be explained by three main factors:
8.2. Critical Comparison of Findings and Associated Limitations
8.2.1. Masking Effects of Standard Regimens
A scientific trial [20] treated participants with antidiabetic regimens not indicated. Therapeutic efficacy of curcumin was not profoundly studied as it was given with potent pharmaceutical agents (e.g. metformin, rosiglitazone, or insulin. Moreover, no analysis of possible drug‐drug interactions that could affect the pharmacokinetics of curcumin has been performed in these designs.
8.2.2. Differences in Formulation and Bioavailability
Studies that did not show appreciable glycemic or lipid benefits [36] commonly used lower dosages of unformulated curcumin. In contrast, the studies with lipid‐based delivery vehicles or nanomicelles [56] showed significant metabolic benefits, confirming the poor gastrointestinal absorption and rapid degradation of unformulated curcumin.
8.2.3. Whole Extract Versus Isolated Curcuminoids Low‐dose turmeric preparations [57]
This effectively decreased kidney inflammatory markers (TGF‐β and IL‐8) but did not change lipid or glucose profiles. This implies that non‐curcuminoid bioactives of whole turmeric might have synergistic anti‐inflammatory effects that differ from those of purified curcumin.
Differences in Target Tissue Biomarkers: In clinical trials for diabetic nephropathy, Yang et al. [58] showed that activating the Nrf2 pathway in peripheral lymphocytes enhanced renal function (lower BUN and microalbumin). Conversely, parallel studies with similar dosages (320 mg/day) did not show any changes in eGFR, proteinuria, or Nrf2 activation, which highlights the considerable variability between studies in the baseline severity of patients and tissue‐level target engagement.
8.3. Main Methodological Recommendations for Further Research
To bridge the gap between preclinical promise and human translation, future clinical research needs to overcome current trial hurdles: Standardize Bioavailability Formulations: Move away from raw turmeric powders to bioenhanced delivery methods (such as phospholipid complexes and nanomicelles). Along with this another area of interest could be Control Background Pharmacotherapy as it is essential to rigorously report, specify and keep constant baseline antidiabetic medicines to evaluate curcumin's net therapeutic contribution and to assess drug‐drug interactions, lastly establishment of tissue specific biomarkers is necessary to verify the systemic effect of curcumin (Table 3).
TABLE 3.
Summary of phases of trials and their key findings and major clinical divergence.
| Phase / Context | Key findings & mechanisms | Major clinical divergence / limitations |
|---|---|---|
| Preclinical Models | Multi‐target action: Nrf2 antioxidant activation, reduction of inflammatory cytokines (TGF‐β, IL‐8), lowered A‐FABP. | Controlled, high‐exposure environments; optimized bio efficacy not limited by human intestinal absorption. |
| Monotherapy / Enhanced Bioavailability | Lowered BMI, FBG, HbA1c, HOMA‐IR, and A‐FABP; lipid improvements via Nanomicellar delivery. | Absolute reductions remain modest (e.g., FBG lowered by ∼18% and HbA1c by ∼11% from baseline). |
| Adjunctive Clinical Setting | Minimal to no added benefit on blood glucose or lipid profiles when added to standard antidiabetic regimens (e.g., metformin, insulin, glibenclamide). | Curcumin's marginal efficacy is often masked or eclipsed by the potency of standard synthetic antidiabetic medications. |
9. Recent Innovations in Nano‐Formulations and Delivery Systems
A wide range of carriers, such as lipids, polymeric complexes, and biocompatible inorganic materials are included in nanoformulations, each of which has special benefits for drug delivery [59]. Notably, because of their capacity to pass through biological barriers and have therapeutic effects inside the body, nanocarriers such dendrimers, nanocrystals, polymersomes, and liposomes have become more well‐known in pharmaceutical applications and biomedical research [60]. Lipid‐based nanocarriers and polymer‐based nanoparticles are flexible drug delivery platforms that provide clear benefits in terms of targeted distribution, tenable qualities, and biocompatibility. Curcumin can be encapsulated in polymer‐based nanoparticles, such as poly (lactic‐co‐glycolic acid) (PLGA) and polyethylene glycol (PEG) derivatives, to improve its solubility and stability and enable regulated release kinetics [61]. Curcumin's therapeutic efficacy can be maximized by customizing these nanoparticles to alter drug release profiles, improve cellular absorption, and produce longer circulation durations in vivo [62]. The hydrophobic cores of lipid‐based nanocarriers, such as liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions, can encapsulate lipophilic substances like curcumin, and they are naturally biocompatible. Phospholipid bilayers, which make up liposomes, can encapsulate curcumin in lipid bilayers or aqueous compartments, allowing for tailored administration to particular tissues or cells while reducing off‐target effects. SLNs are good options for encapsulating curcumin and getting over its intrinsic bioavailability restrictions because of its stability and prolonged release advantages [63]. Oil‐in‐water or water‐in‐oil nanoemulsions offer a stable delivery system for hydrophobic substances like curcumin, improving its therapeutic efficiency and bioavailability [64].
The prevalence of lipid‐based nanocarriers and polymer‐based nanoparticles in nanoformulation studies demonstrates their adaptability and efficiency in tackling the difficulties related to curcumin delivery. Researchers can unlock curcumin's full therapeutic potential for a variety of applications, such as antimicrobial, antioxidant, anti‐inflammatory, neuroprotective, and anticancer interventions, by utilizing the special qualities of these nanocarriers to overcome obstacles to its clinical use [65]. Additionally, new delivery systems like stimuli‐responsive carriers and hybrid nanoparticles can be developed thanks to developments in nanotechnology, which will increase the bioavailability and effectiveness of curcumin‐based treatments [66].
Notwithstanding their many benefits, nanoparticles have a number of intrinsic drawbacks that varies depending on the kind. Despite their potential for drug delivery, polymer nanoparticles are frequently beset by problems such poor stability, low encapsulation effectiveness for hydrophilic medicines, and difficulties in scaling up manufacturing. Furthermore, using organic solvents in traditional preparation techniques can degrade encapsulated active compounds and provide safety hazards to people. Despite their effectiveness in improving drug administration and bioavailability, liposomal nanoparticles have drawbacks, including rapid in vivo elimination, possible sterility problems, and the possibility of drug leakage [67]. Furthermore, it is feared that liposomal nanomedicines can unintentionally target healthy tissues, resulting in immunological responses and cytotoxicity. Despite their special qualities and uses in many other industries, metal nanoparticles can cause issues with biocompatibility and toxicity. Comprehensive research is required to understand the impacts of metal nanoparticles on both internal and exterior environments, as there is increasing evidence that they may cause toxicological consequences in biological systems [68]. Furthermore, some metal nanoparticle systems' production of active oxygen can exacerbate inflammation and oxidative stress, which emphasizes the need for careful assessment of their safety profiles (Table 4).
TABLE 4.
Nanocarrier systems for the Curcumin delivery.
| Nanocarrier system | Typical characteristics / examples for curcumin delivery | Major advantages | Limitations | Relevance to diabetic neuropathy |
|---|---|---|---|---|
| Nanoemulsions | Oil‐in‐water systems containing curcumin/curcuminoids, oil phase, surfactant and co‐surfactant; generally produce nanoscale droplets | Enhanced solubility and dissolution of poorly water‐soluble curcumin; improved oral absorption; relatively simple preparation; scalable; suitable for liquid or oral formulations | Physical instability such as Ostwald ripening, creaming or coalescence; relatively high surfactant requirement; limited protection against chemical degradation in some formulations | High relevance. Improved systemic exposure may enhance curcumin's antioxidant, anti‐inflammatory and glucose‐regulatory effects implicated in diabetic nerve injury. Particularly attractive for oral administration in chronic DN management |
| Polymeric nanoparticles | Curcumin encapsulated within biodegradable polymers such as PLGA, PLA or chitosan | Controlled and sustained drug release; protection from degradation; improved bioavailability; potential for surface modification and targeted delivery | More complex manufacturing; polymer‐related toxicity must be evaluated; possible burst release; relatively high production cost | High relevance. Sustained exposure may be beneficial for chronic oxidative stress and neuroinflammation associated with DN. Surface modification could potentially facilitate tissue‐specific delivery |
| Lipid nanoparticles (SLN) | Solid lipid matrix incorporating curcumin; stabilized with surfactants | High biocompatibility; improved solubility and bioavailability; protection from degradation; controlled release; relatively suitable for large‐scale production | Drug expulsion during storage due to lipid crystallization; limited drug‐loading capacity for some compounds; possible polymorphic transitions | High relevance. Enhanced systemic availability and prolonged release may support antioxidant and anti‐inflammatory activity against oxidative neuronal damage |
| Nanostructured lipid carriers (NLCs) | Mixture of solid and liquid lipids providing a less ordered lipid matrix than SLNs | Higher drug‐loading capacity than SLNs; improved physical stability; controlled release; reduced drug expulsion; enhanced bioavailability | Formulation optimization can be complex; surfactant‐related toxicity and long‐term stability require evaluation | Very high relevance. Increased loading and sustained curcumin delivery may be useful for prolonged suppression of oxidative stress, inflammatory mediators and neuronal dysfunction in DN |
| Liposomes | Phospholipid bilayer vesicles capable of carrying hydrophobic curcumin within the lipid phase | Excellent biocompatibility; ability to encapsulate diverse compounds; improved solubility; surface modification possible; established drug‐delivery platform | Physical instability; leakage and oxidation of lipids; relatively expensive production; limited long‐term storage stability | High relevance. Can improve curcumin exposure and potentially facilitate delivery to tissues involved in diabetic nerve injury; surface modification may further improve targeting |
| Phytosomes/lipid–phospholipid complexes | Curcumin complexed with phospholipids to improve absorption; examples include curcumin–phosphatidylcholine complexes | Improved intestinal absorption and bioavailability; relatively simple compared with sophisticated nanoparticles; good suitability for oral administration | Usually provides less controlled release than polymeric nanoparticles; phospholipid oxidation and formulation stability may be concerns | Moderate–high relevance. Improved oral bioavailability may increase systemic antioxidant and anti‐inflammatory effects relevant to neuropathic pain and nerve dysfunction |
| Dendrimers | Highly branched nanoscale polymers with internal cavities and multiple surface functional groups for drug conjugation/encapsulation | Precise molecular architecture; high surface functionality; potentially high drug‐loading capacity; amenable to targeting and controlled release | Complex synthesis; relatively expensive; concerns regarding surface‐associated toxicity and biodegradability | Potentially high relevance. Surface functionalization could facilitate targeted delivery to pathways or tissues involved in neuroinflammation and oxidative stress, although DN‐specific evidence remains limited |
| Nanogels | Three‐dimensional cross‐linked polymeric networks capable of incorporating curcumin and releasing it in response to environmental stimuli | High water content; good biocompatibility; controlled/stimuli‐responsive release; protection of encapsulated compounds | Complex formulation; limited clinical translation; possible instability and scale‐up challenges | Potential relevance. Controlled release could maintain therapeutic curcumin concentrations and potentially reduce oxidative and inflammatory damage in peripheral nerves |
| Mesoporous silica nanoparticles | Porous inorganic nanoparticles with large surface area for curcumin loading | High surface area; tunable pore size; high loading capacity; controlled release; surface functionalization | Limited biodegradability compared with organic nanocarriers; long‐term safety and accumulation require careful evaluation | Emerging relevance. Targeted and controlled curcumin delivery could potentially improve neuroprotective activity, but evidence specifically in DN remains comparatively limited |
| Metallic nanoparticles | Gold, silver or other metal‐based nanoparticles used as carriers or functional nanomaterials | High surface area; tunable physicochemical properties; potential for imaging and targeted delivery | Potential metal‐associated toxicity, oxidative effects, accumulation and regulatory concerns | Limited/experimental relevance. Although they offer advanced targeting possibilities, safety concerns and limited DN‐specific evidence currently restrict their therapeutic application |
| Exosomes | Naturally derived vesicles capable of transporting bioactive molecules; potentially engineered or loaded with curcumin | Excellent biocompatibility; natural cellular communication; potential tissue targeting; ability to cross biological barriers | Difficult isolation and characterization; low loading efficiency in some systems; batch variability; complex manufacturing and regulatory challenges | Emerging/high potential relevance. Their natural targeting properties may be advantageous for delivering curcumin to injured neural tissues and modulating neuroinflammation, oxidative stress and neuronal repair |
| Solid lipid–based hybrid nanoparticles | Combination of lipid and polymeric components to exploit properties of both systems | Improved stability, loading, controlled release and bioavailability; potentially combines advantages of lipid and polymeric carriers | More complex formulation and characterization; scale‐up and regulatory challenges | High potential relevance. Sustained and enhanced curcumin exposure may be beneficial for the chronic inflammatory and oxidative mechanisms underlying DN |
10. Discussion and Conclusion
Although it hasn't been clinically proven yet, curcumin is a promising treatment option for diabetes and diabetic neuropathy. While curcumin's well‐documented antioxidant, anti‐inflammatory, hypoglycemic, and neuroprotective properties substantiate its therapeutic potential across interrelated pathways—including oxidative stress, insulin resistance, neuroinflammation, mitochondrial dysfunction, and peripheral nerve injury—existing clinical and translational evidence must be interpreted with caution. In contrast to previous reviews that predominantly focus on broad antidiabetic actions or isolated anti‐inflammatory mechanisms, our manuscript provides an integrative, bench‐to‐bedside framework to bridge these translational gaps. Specifically, we connect: Sustainable Sourcing: Green extraction and isolation techniques for optimized curcumin recovery. Systems‐Level Target Mapping: High‐throughput omics (transcriptomics, metabolomics, and proteomics) to map multi‐target cellular networks in DN. Targeted Delivery Systems: Advanced nano‐formulations (nanomicelles, liposomes, and polymeric systems) engineered to overcome low oral bioavailability and bypass blood‐nerve barrier constraints.
While preclinical research consistently shows positive effects, clinical results are still inconsistent due to differences in dose, curcuminoid composition, formulation, bioavailability, treatment duration, patient characteristics, and concurrent antidiabetic therapy. Therefore, verified clinical effectiveness should not be equated with mechanistic efficacy. Curcumin's weak water solubility, quick metabolism, and low systemic bioavailability are its main translational limitations. The long‐term safety, reproducibility, scalability, pharmacokinetic behavior, and clinical superiority of nanoemulsions, lipid nanoparticles, polymeric nanoparticles, liposomes, and other advanced delivery systems over conventional preparations are still not well established, despite the fact that they can increase exposure. Additionally, there is far less proof that diabetic neuropathy may be prevented or reversed in carefully planned human studies than there is for glycemic or biochemical changes. As a result, curcumin should now be viewed as a possible supplement to proven antidiabetic and neuropathy‐management techniques rather than a substitute treatment. Instead of primarily depending on surrogate biochemical markers, future research should prioritize standardized, bioavailability‐enhanced formulations and sufficiently powered, long‐term randomized controlled trials using clinically meaningful neuropathy endpoints, such as pain severity, nerve conduction parameters, sensory function, and quality of life. Systematic research should also be done on dose‐response relationships, pharmacokinetic‐pharmacodynamic correlations, and interactions with traditional antidiabetic and neuropathic painkillers. Patient heterogeneity, comorbidities, formulation‐dependent safety, and regulatory requirements should all receive special consideration. Curcumin's therapeutic potential will ultimately depend on whether these biological effects can be converted into repeatable, clinically significant, and safe advantages for patients with diabetes and diabetic neuropathy rather than only on its wide mechanistic action.
Author Contributions
Sanket Sharma: ‐manuscript writing. Rashmi Singh: manuscript writing. Radha Goel: analysis. Praveen Kumar Gaur and Kanak Lata: ‐ validation. Rosaline Mishra: outline and concept
Funding
The author(s) reported there is no funding associated with the work featured in this article.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgements
“The authors acknowledge the use of QuillBot and Gemini for minimal paraphrasing and for improving textual flow and coherence of specific sections of this manuscript.”
Biographies
Mr. Sanket Sharma Research scholar at Metro College of Health Sciences and Research.
Dr. Rosaline Mishra (M.Pharm ‐ Pharmaceutical Chemistry, Ph.D.), Professor and Head of the Department of Pharmaceutical Chemistry at Metro College of Health Sciences and Research Pharmacy, brings over 13 years of dedicated academic and research experience to her role. With a prolific publication record boasting over 40 research articles, review papers, and book chapters, as well as 4 granted patents, Dr. Mishra has made significant contributions to her field. Dr. Mishra has earned her Ph.D. from Uttarakhand Technical University, Dehradun, India, in 2022. Recognized for her exceptional teaching skills, Dr. Mishra was honored with the prestigious “Dynamic Professor of the Year” award in 2023 at the Education Excellence Awards show. Her research interests encompass the molecular mechanisms underlying metabolic syndrome and its associated pathologies, as well as the exploration of marine flora as a potential source of phytopharmaceuticals. Apart from academic contributions, Dr. Mishra is a respected reviewer for renowned journals published by Elsevier, Taylor & Francis, Bentham Science, Springer, and so on further strengthening her scientific reputation.

Ms. Rashmi Singh is an Assistant Professor at Metro College of Health Sciences & Research with more than 6 years of teaching experience in the field of pharmaceutical sciences. She completed her Bachelor of Pharmacy (B.Pharm) and Master of Pharmacy (M.Pharm) from the Lloyd Institute of Management and Technology, Greater Noida, where she developed a strong academic and research foundation. She is actively involved in teaching and mentoring undergraduate pharmacy students and promoting research‐oriented learning. Her academic interests include pharmaceutical analysis, analytical method development, and formulation research. She has authored and co‐authored several research publications in reputed journals. In recognition of her dedication to academics and research, she has received the Best Academic Teacher Award for outstanding student results and an Appreciation Award for her valuable contributions to research publications and academic development.

Dr. Radha Goel Professor and Academic Head at Lloyd Institute of management and Technology, has more than 19 years of academic and research experience. She is an alumnus of Jamia Hamdard, Hamdard University, New Delhi, one of India's Best Research Institutes. Dr. Radha received the Best Teacher Award under ‘Overall Category’ by Dr. APJ Abdul Kalam University, Lucknow in 2022. She received a research grant and a travel grant from AKTU, Lucknow. She has published more than 40 scientific research and review articles in imperative journals with good impact factors, many patents published, and authored 6 books. She received the best teacher award in 2013 from the ITS group of institutions. She has supervised Ph.D. and 18 PG students. She is a nominee team member in CPCSEA. She has been a peer reviewer as well as an editorial board member of several reputed journals. Her main research areas are Neuropharmacology, Neuropsychopharmacology, Indigenous Pharmacology, Phytotherapy, and Ethnopharmacology.
Dr. Praveen Kumar Gaur currently Principal and Professor at Metro College of Health Sciences & Research, Greater Noida, is a distinguished academician with over 16 years of experience. He specializes in novel drug delivery and applied research, guiding numerous M.Pharm and PhD students. Awarded “Best Teacher in Pharmacy” by Dr. APJ Abdul Kalam Technical University, Lucknow, Dr. Gaur is also a former Board of Studies member. His prolific research includes over 60 articles in high‐impact journals and two books, alongside two Indian patents. He serves on editorial boards of international journals and received the Visvesvaraya Research Promotion Scheme (VRPS) grant. Dr. Gaur has successfully organized international and national seminars and an AICTE‐ATAL funded FDP, reflecting strong leadership. His life mantra is “Education is a commitment to excellence in teaching and learning”.

Dr. Kanak Lata is an accomplished professional with over 22 years of experience in teaching, training, and administration. Holding a doctorate in management and professional degrees in pharmacy, hospital administration, and education/marketing, she possesses a unique blend of expertise. Dr. Lata has a proven track record in academic leadership, including establishing an AICTE‐approved technical college. She's co‐authored a book on Pharmaceutical Jurisprudence and IPR, and presented papers in HRM and Marketing Management at national and international forums. A certified Universal Human Values faculty, she actively contributes to the AICTE‐NCCIP and AKTU UHV cell. Recognized with two Appreciation Awards from Ratriya Shaikshik Mahasangh for her contributions to education, Dr. Lata also chairs various institutional committees such as Anti‐ragging and Women Safety. She's a lifetime member of the Academy of Hospital Administration and the Indian Pharmacy Graduate Association.

Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Grunbaum S., “Understanding Diabetes Mellitus Causes, Symptoms, and Complications,” Biomed J Sci Tech Res 50, no. 3 (2023): 41622–41628, 10.26717/BJSTR.2023.50.007946. [DOI] [Google Scholar]
- 2. Sun H., Saeedi P., and Karuranga S., “IDF Diabetes Atlas: Global, Regional and Country‐level Diabetes Prevalence Estimates for 2021 and Projections for 2045,” Diabetes Research and Clinical Practice 183 (2022): 109119, 10.1016/j.diabres.2021.109119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Papanas N. and Ziegler D., “Risk Factors and Comorbidities in Diabetic Neuropathy: An Update,” Rev Diabet Stud RDS 12, no. 1–2 (2015): 48–62, 10.1900/RDS.2015.12.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Yang Y., Zhao B., and Wang Y., “Diabetic Neuropathy: Cutting‐edge Research and Future Directions,” Signal Transduction Target Therapy 10 (2025): 132, 10.1038/s41392-025-02175-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. World Health OrganizationDiabetes [Internet]. [cited 2026 Aug 31]. Available from:, https://www.who.int/health‐topics/diabetes.
- 6. Yang Y., Zhao B., and Wang Y., “Diabetic Neuropathy: Cutting‐edge Research and Future Directions,” Signal Transduction Target Therapy 10, no. 1 (2025): 132, 10.1038/s41392-025-02175-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Panahi Y., Khalili N., and Sahebi E., “Effects of Curcuminoids plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients With Type 2 Diabetes Mellitus: A Randomized Double‐Blind Placebo‐Controlled Trial,” Drug Resource 68, no. 7 (2018): 403–409, 10.1055/s-0044-101752. [DOI] [PubMed] [Google Scholar]
- 8. He H. J., Wang G. Y., Gao Y., Ling W. H., Yu Z. W., and Jin T. R., “Curcumin Attenuates Nrf2 Signaling Defect, Oxidative Stress in Muscle and Glucose Intolerance in High Fat Diet‐fed Mice,” World Journal Diabetes 3, no. 5 (2012): 94–104, 10.4239/wjd.v3.i5.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Xavier S., Sadanandan J., George N., and Paulose C. S., “β2‐adrenoceptor and insulin receptor expression in the skeletal muscle of streptozotocin induced diabetic rats: Antagonism by vitamin D3 and curcumin,” European Journal of Pharmacology 687, no. 1–3 (2012): 14–20, 10.1016/j.ejphar.2012.02.050. [DOI] [PubMed] [Google Scholar]
- 10. Rukkumani R. and Menon V. P., “Protective Effects of Curcumin and Photo‐irradiated Curcumin on Circulatory Lipids and Lipid Peroxidation Products in Alcohol and Polyunsaturated Fatty Acid‐induced Toxicity,” Phytotherapy Research PTR 17, no. 8 (2003): 925–929, 10.1002/ptr.1254. [DOI] [PubMed] [Google Scholar]
- 11. Shanmugam M. K., Rane G., and Kanchi M. M., “The Multifaceted Role of Curcumin in Cancer Prevention and Treatment,” MoleculesMolecules 20, no. 2 (2015): 2728–2769, 10.3390/molecules20022728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Tripathy S., Verma D. K., and Thakur M., “Curcumin Extraction, Isolation, Quantification and Its Application in Functional Foods: A Review with a Focus on Immune Enhancement Activities and COVID‐19,” Frontiers in Nutrition 8 (2021): 747956, 10.3389/fnut.2021.747956. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Kim D. C., Kim S. H., and Choi B. H., “Curcuma Longa Extract Protects Against Gastric Ulcers by Blocking H2 Histamine Receptors,” Biological & pharmaceutical bulletin 28, no. 12 (2005): 2220–2224, 10.1248/bpb.28.2220. [DOI] [PubMed] [Google Scholar]
- 14. Ravikumar N. and Kavitha C. N., “Therapeutic Potential of Curcumin on Immune Dysregulation in Comorbid Diabetic Asthma in Mice,” Biomedical Pharmacological Journal 13, no. 2 (2020): 821–831. [Google Scholar]
- 15. Romero M. J., Bosch‐Morell F., Romero B., Rodrigo J. M., Serra M. A., and Romero F. J., “Serum Malondialdehyde: Possible Use for the Clinical Management of Chronic hepatitis C Patients,” Free Radical Biological Medicine 25, no. 9 (1998): 993–997, 10.1016/s0891-5849(98)00118-x. [DOI] [PubMed] [Google Scholar]
- 16. Bosman B., “Testing of Lipoxygenase Inhibitors, Cyclooxygenase Inhibitors, Drugs With Immunomodulating Properties and some Reference Antipsoriatic Drugs in the Modified Mouse Tail Test, an Animal Model of Psoriasis,” Skin Pharmacological Off Journal of Skin Pharmacological Society 7, no. 6 (1994): 324–334, 10.1159/000211314. [DOI] [PubMed] [Google Scholar]
- 17. Guo S. P., Chang H. C., Lu L. S., Liu D. Z., and Wang T. J., “Activation of Kelch‐Like ECH‐associated Protein 1/Nuclear Factor Erythroid 2‐related Factor 2/Antioxidant Response Element Pathway by Curcumin Enhances the Anti‐oxidative Capacity of Corneal Endothelial Cells,” Biomed Pharmacotherapy Biomedicine Pharmacotherapy 141 (2021): 111834, 10.1016/j.biopha.2021.111834. [DOI] [PubMed] [Google Scholar]
- 18. Na L. X., Yan B. L., Jiang S., Cui H. L., Li Y., and Sun C. H., “Curcuminoids Target Decreasing Serum Adipocyte‐fatty Acid Binding Protein Levels in Their Glucose‐lowering Effect in Patients With Type 2 Diabetes,” Biomed Environ Sci BES 27, no. 11 (2014): 902–906, 10.3967/bes2014.127. [DOI] [PubMed] [Google Scholar]
- 19. Graupera I., Coll M., and Pose E., “Adipocyte Fatty‐acid Binding Protein Is Overexpressed in Cirrhosis and Correlates With Clinical Outcomes,” Scientific Reports 7, no. 1 (2017), 10.1038/s41598-017-01709-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Rahimi H. R., Mohammadpour A. H., Dastani M., Jaafari M. R., and Abnous K., “The Effect of Nano‐curcumin on HbA1c, Fasting Blood Glucose, and Lipid Profile in Diabetic Subjects: A Randomized Clinical Trial,” Avicenna J Phytomedicine 6, no. 5 (2016): 567–577. [PMC free article] [PubMed] [Google Scholar]
- 21. Yang H., Xu W., and Zhou Z., “Curcumin Attenuates Urinary Excretion of Albumin in Type II Diabetic Patients With Enhancing Nuclear Factor Erythroid‐derived 2‐Like 2 (Nrf2) System and Repressing Inflammatory Signaling Efficacies,” Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 123, no. 6 (2015): 360–367, 10.1055/s-0035-1545345. [DOI] [PubMed] [Google Scholar]
- 22. Jiménez‐Osorio A. S., García‐Niño W. R., and González‐Reyes S., “The Effect of Dietary Supplementation with Curcumin on Redox Status and Nrf2 Activation in Patients with Nondiabetic or Diabetic Proteinuric Chronic Kidney Disease: A Pilot Study,” J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found 26, no. 4 (2016): 237–244, 10.1053/j.jrn.2016.01.013. [DOI] [PubMed] [Google Scholar]
- 23. (PDF) Oral Supplementation of Turmeric Attenuates Proteinuria, Transforming Growth Factor‐β and Interleukin‐8 Levels in Patients With Overt Type 2 Diabetic Nephropathy: A Randomized, Double‐blind and Placebo‐controlled Study. ResearchGate [Internet] Accessed 2026 Jul 19 Available from:, https://www.researchgate.net/publication/51179292_Oral_supplementation_of_turmeric_attenuates_proteinuria_transforming_growth_factor‐b_and_interleukin‐8_levels_in_patients_with_overt_type_2_diabetic_nephropathy_A_randomized_double‐blind_and_placebo‐c. [DOI] [PubMed]
- 24. Jareño E. J., Bosch‐Morell F., Fernández‐Delgado R., Donat J., and Romero F. J., “Serum Malondialdehyde in HIV Seropositive Children,” Free Radic Biol Med 24, no. 3 (1998): 503–506, 10.1016/s0891-5849(97)00168-8. [DOI] [PubMed] [Google Scholar]
- 25. Sancho‐Tello M., Muriach M., and Barcia J., “Chronic Alcohol Feeding Induces Biochemical, Histological, and Functional Alterations in Rat Retina,” Alcohol and Alcoholism 43, no. 3 (2008): 254–260, 10.1093/alcalc/agn006. [DOI] [PubMed] [Google Scholar]
- 26. Daniel S., Limson J. L., Dairam A., Watkins G. M., and Daya S., “Through Metal Binding, Curcumin Protects Against Lead‐ and Cadmium‐induced Lipid Peroxidation in Rat Brain Homogenates and Against Lead‐induced Tissue Damage in Rat Brain,” Journal of Inorganic Biochemistry 98, no. 2 (2004): 266–275, 10.1016/j.jinorgbio.2003.10.014. [DOI] [PubMed] [Google Scholar]
- 27. Taketo M. M., “Cyclooxygenase‐2 Inhibitors in Tumorigenesis (Part II),” JNCI J Natl Cancer Inst 90, no. 21 (1998): 1609–1620, 10.1093/jnci/90.21.1609. [DOI] [PubMed] [Google Scholar]
- 28. Suhail S., Gupta S., Kumar V., and Gupta O. P., “Role of Curcumin in Oral Cancer Prevention,” Fractal Geom Nonlinear Anal Med Biol 1, no. 3 (2016), 10.15761/FGNAMB.1000119. [DOI] [Google Scholar]
- 29. Wu X., Zhou X., Lai S., Liu J., and Qi J., “Curcumin Activates Nrf2/HO‐1 Signaling to Relieve Diabetic Cardiomyopathy Injury by Reducing ROS in Vitro and in Vivo,” Faseb Journal 36, no. 9 (2022): e22505, 10.1096/fj.202200543RRR. [DOI] [PubMed] [Google Scholar]
- 30. Liu D., Schwimer J., Liu Z., Woltering E. A., and Greenway F. L., “Antiangiogenic Effect of Curcumin in Pure versus in Extract Forms,” Pharmaceutical Biology 46, no. 10–11 (2008): 677–682, 10.1080/13880200802215826. [DOI] [Google Scholar]
- 31. Martin R. C. G., Aiyer H. S., Malik D., and Li Y., “Effect on Pro‐inflammatory and Antioxidant Genes and Bioavailable Distribution of Whole Turmeric vs Curcumin: Similar Root but Different Effects,” Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 50, no. 2 (2012): 227–231, 10.1016/j.fct.2011.10.070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Chuengsamarn S., Rattanamongkolgul S., Phonrat B., Tungtrongchitr R., and Jirawatnotai S., “Reduction of Atherogenic Risk in Patients With Type 2 Diabetes by Curcuminoid Extract: A Randomized Controlled Trial,” Journal of Nutritional Biochemistry 25, no. 2 (2014): 144–150, 10.1016/j.jnutbio.2013.09.013. [DOI] [PubMed] [Google Scholar]
- 33. Hahad O., Prochaska J. H., Daiber A., and Muenzel T., “Environmental Noise‐Induced Effects on Stress Hormones, Oxidative Stress, and Vascular Dysfunction: Key Factors in the Relationship Between Cerebrocardiovascular and Psychological Disorders,” Oxid Med Cell Longev 2019 (2019): 4623109, 10.1155/2019/4623109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. D'Angelantonio M., D'Erme M., Pecci L., and Fontana M., “The Interaction of Hypotaurine and Other Sulfinates With Reactive Oxygen and Nitrogen Species: A Survey of Reaction Mechanisms,” Advances in Experimental Medicine and Biology 975, no. Pt 1 (2017): 573–583, 10.1007/978-94-024-1079-2_45. [DOI] [PubMed] [Google Scholar]
- 35. Oršolić N., Karlović D., and Peitl V., “Flavonols in Action: Targeting Oxidative Stress and Neuroinflammation in Major Depressive Disorder,” International Journal of Molecular Sciences 24, no. 8 (2023): 6888, 10.3390/ijms24086888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Spranger J., Kroke A., and Möhlig M., “Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: Results of the Prospective Population‐based European Prospective Investigation Into Cancer and Nutrition (EPIC)‐Potsdam Study,” DiabetesDiabetes 52, no. 3 (2003 Mar): 812–817, 10.2337/diabetes.52.3.812. [DOI] [PubMed] [Google Scholar]
- 37. Vatsavai L. K. and Kilari E. K., “Influence of Curcumin on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Animal Models,” J Exp Pharmacol 8 (2016): 69–76, 10.2147/JEP.S117042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Ahn J., Lee H., Kim S., and Ha T., “Curcumin‐induced Suppression of Adipogenic Differentiation Is Accompanied by Activation of Wnt/Beta‐catenin Signaling,” American Journal of Physiology. Cell Physiology 298, no. 6 (2010): C1510–1516, 10.1152/ajpcell.00369.2009. [DOI] [PubMed] [Google Scholar]
- 39. Horton J. D., Shah N. A., and Warrington J. A., “Combined Analysis of Oligonucleotide Microarray Data From Transgenic and Knockout Mice Identifies Direct SREBP Target Genes,” PNAS 100, no. 21 (2003): 12027–12032, 10.1073/pnas.1534923100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Pari L. and Murugan P., “Antihyperlipidemic Effect of Curcumin and Tetrahydrocurcumin in Experimental Type 2 Diabetic Rats,” Renal failure 29, no. 7 (2007): 881–889, 10.1080/08860220701540326. [DOI] [PubMed] [Google Scholar]
- 41. Anand P., Kunnumakkara A. B., Newman R. A., and Aggarwal B. B., “Bioavailability of Curcumin: Problems and Promises,” Mol Pharm 4, no. 6 (2007): 807–818, 10.1021/mp700113r. [DOI] [PubMed] [Google Scholar]
- 42. Al‐Ali K. and El‐Badry Y. A. M., “Dual Effect of Curcumin‐Zinc Complex in Controlling Diabetes Mellitus in Experimentally Induced Diabetic Rats,” Biological & pharmaceutical bulletin 39, no. 11 (2016): 1774–1780, 10.1248/bpb.b16-00137. [DOI] [PubMed] [Google Scholar]
- 43. El‐Far Y. M., Zakaria M. M., Gabr M. M., El Gayar A. M., Eissa L. A., and El‐Sherbiny I. M., “Nanoformulated Natural Therapeutics for Management of Streptozotocin‐induced Diabetes: Potential Use of Curcumin Nanoformulation,” Nanomed 12, no. 14 (2017): 1689–1711, 10.2217/nnm-2017-0106. [DOI] [PubMed] [Google Scholar]
- 44. Fujimoto K. and Polonsky K. S., “Pdx1 and Other Factors That Regulate Pancreatic Beta‐cell Survival,” Diabetes, Obesity & Metabolism 11, no. Suppl 4 (2009): 30–37, 10.1111/j.1463-1326.2009.01121.x. [DOI] [PMC free article] [PubMed]
- 45. Taylor B. L., Benthuysen J., and Sander M., “Postnatal β‐cell Proliferation and Mass Expansion Is Dependent on the Transcription Factor Nkx6.1,” DiabetesDiabetes 64, no. 3 (2015): 897–903, 10.2337/db14-0684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Nelson K. M., Dahlin J. L., Bisson J., Graham J., Pauli G. F., and Walters M. A., “The Essential Medicinal Chemistry of Curcumin,” Journal of Medicinal Chemistry 60, no. 5 (2017): 1620–1637, 10.1021/acs.jmedchem.6b00975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Takanohashi T., Kubo S., Arisaka H., Shinkai K., and Ubukata K., “Contribution of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 to Hepatic Uptake of Nateglinide, and the Prediction of Drug‐drug Interactions via these Transporters,” Journal of Pharmacy and Pharmacology 64, no. 2 (2012): 199–206, 10.1111/j.2042-7158.2011.01389.x. [DOI] [PubMed] [Google Scholar]
- 48. Tamraz B., Fukushima H., and Wolfe A. R., “OATP1B1‐related Drug‐drug and Drug‐gene Interactions as Potential Risk Factors for Cerivastatin‐induced Rhabdomyolysis,” Pharmacogenetics and genomics 23, no. 7 (2013): 355–364, 10.1097/FPC.0b013e3283620c3b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. van de Steeg E., Greupink R., and Schreurs M., “Drug‐drug Interactions Between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1,” Drug Metab Dispos Biol Fate Chem 41, no. 3 (2013): 592–601, 10.1124/dmd.112.049023. [DOI] [PubMed] [Google Scholar]
- 50. Chait A. and Goldberg I., “Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions,” Current Diabetes Reports 17, no. 11 (2017): 112, 10.1007/s11892-017-0942-8. [DOI] [PubMed] [Google Scholar]
- 51. Anuchapreeda S., Leechanachai P., Smith M. M., Ambudkar S. V., and ngarm L. P., “Modulation of P‐glycoprotein Expression and Function by Curcumin in Multidrug‐resistant human KB Cells,” Biochemical Pharmacology 64, no. 4 (2002): 573–582, 10.1016/s0006-2952(02)01224-8. [DOI] [PubMed] [Google Scholar]
- 52. Chearwae W., Anuchapreeda S., Nandigama K., Ambudkar S. V., and Limtrakul P., “Biochemical Mechanism of Modulation of human P‐glycoprotein (ABCB1) by Curcumin I, II, and III Purified From Turmeric Powder,” Biochemical Pharmacology 68, no. 10 (2004): 2043–2052, 10.1016/j.bcp.2004.07.009. [DOI] [PubMed] [Google Scholar]
- 53. Panahi Y., Khalili N., and Sahebi E., “Curcuminoids Modify Lipid Profile in Type 2 Diabetes Mellitus: A Randomized Controlled Trial,” Complementary Therapies in Medicine 33 (2017): 1–5, 10.1016/j.ctim.2017.05.006. [DOI] [PubMed] [Google Scholar]
- 54. Na L. X., Li Y., and Pan H. Z., “Curcuminoids Exert Glucose‐lowering Effect in Type 2 Diabetes by Decreasing Serum Free Fatty Acids: A Double‐blind, Placebo‐controlled Trial,” Molecular Nutrition & Food Research 57, no. 9 (2013 Sep): 1569–1577, 10.1002/mnfr.201200131. [DOI] [PubMed] [Google Scholar]
- 55. Study Details | NCT03019848 | Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease | ClinicalTrialsgov [Internet] (2026): Aug 31, https://clinicaltrials.gov/study/NCT03019848.
- 56. Chuengsamarn S., Rattanamongkolgul S., Luechapudiporn R., Phisalaphong C., and Jirawatnotai S., “Curcumin Extract for Prevention of Type 2 Diabetes,” Diabetes Care 35, no. 11 (2012): 2121–2127, 10.2337/dc12-0116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Li Y., Jiao J., and Qi Y., “Curcumin: A Review of Experimental Studies and Mechanisms Related to Periodontitis Treatment,” Journal of Periodontal Research 56, no. 5 (2021): 837–847, 10.1111/jre.12914. [DOI] [PubMed] [Google Scholar]
- 58. Yang Y., Li W., Li Y., Wang Q., Gao L., and Zhao J., “Dietary Lycium Barbarum Polysaccharide Induces Nrf2/ARE Pathway and Ameliorates Insulin Resistance Induced by High‐fat via Activation of PI3K/AKT Signaling,” Oxid Med Cell Longev 2014 (2014): 145641, 10.1155/2014/145641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Mitchell M. J., Billingsley M. M., Haley R. M., Wechsler M. E., Peppas N. A., and Langer R., “Engineering Precision Nanoparticles for Drug Delivery,” Nature Reviews Drug Discovery 20, no. 2 (2021): 101–124, 10.1038/s41573-020-0090-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Bhardwaj H. and Jangde R. K., “Current Updated Review on Preparation of Polymeric Nanoparticles for Drug Delivery and Biomedical Applications,” Nanotechnol 2 (2023): 100013, 10.1016/j.nxnano.2023.100013. [DOI] [Google Scholar]
- 61. Wang S., Chen Y., Guo J., and Huang Q., “Liposomes for Tumor Targeted Therapy: A Review,” International Journal of Molecular Sciences 24, no. 3 (2023): 2643, 10.3390/ijms24032643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Grathwohl T., “Development of Curcumin and Docetaxel co‐loaded Actively Targeted PLGA Nanoparticles to Overcome Blood Brain Barrier,” Pharma Excipients 66 (2021), 10.1016/j.jddst.2021.102867. [DOI] [Google Scholar]
- 63. Pareek A., Kothari R., and Pareek A., “Development of a New Inhaled Swellable Microsphere System for the Dual Delivery of Naringenin‐loaded Solid Lipid Nanoparticles and Doxofylline for the Treatment of Asthma,” Eur J Pharm Sci Off J Eur Fed Pharm Sci 193 (2024): 106642, 10.1016/j.ejps.2023.106642. [DOI] [PubMed] [Google Scholar]
- 64. null P., Sambhakar S., and Malik R., “Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs,” Scientifica 2023 (2023): 6640103, 10.1155/2023/6640103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Dehzad M. J., Ghalandari H., Nouri M., and Askarpour M., “Antioxidant and Anti‐inflammatory Effects of Curcumin/Turmeric Supplementation in Adults: A GRADE‐assessed Systematic Review and Dose‐response Meta‐analysis of Randomized Controlled Trials,” CytokineCytokine 164 (2023): 156144, 10.1016/j.cyto.2023.156144. [DOI] [PubMed] [Google Scholar]
- 66. El‐Sawy H. S., AM A.‐A., Ahmed T. A., El‐Say K. M., and Torchilin V. P., “Stimuli‐Responsive Nano‐Architecture Drug‐Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives,” ACS Nano 12, no. 11 (2018): 10636–10664, 10.1021/acsnano.8b06104. [DOI] [PubMed] [Google Scholar]
- 67. Gbian D. L. and Omri A., “Lipid‐Based Drug Delivery Systems for Diseases Managements,” Biomedicines 10, no. 9 (2022): 2137, 10.3390/biomedicines10092137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Kothaplly S., Alukapally S., Nagula N., and Maddela R., “Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans under Fasting Conditions,” Advances in Therapy 39, no. 5 (2022): 2128–2138, 10.1007/s12325-022-02081-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
